Updates on Treatment of Gemcitabine-Refractory Pancreatic Adenocarcinoma

被引：0
|
作者：
Makrilia, Nektaria [1 ]
Syrigos, Kostas N. [1 ]
Saif, Muhammad W. [2 ,3 ]
机构：
[1] Sotiria Gen Hosp, Athens Med School, Dept Med 3, Oncol Unit, Athens, Greece
[2] Columbia Univ Coll Phys & Surg, 177 Ft Washington Ave,Suite 6-435, New York, NY 10032 USA
[3] New York Presbyterian Hosp, Pancreas Ctr, New York, NY USA
来源：
JOURNAL OF THE PANCREAS | 2011年 / 12卷 / 04期
关键词：
capecitabine; lapatinib; Pancreatic Neoplasms; S-1; Treatment Failure;
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Gemcitabine monotherapy and gemcitabine-based regimens are the current standard of care for locally advanced or metastatic pancreatic adenocarcinoma. However, there is still great controversy over the role of salvage chemotherapy after failure of gemcitabine. This review is an update on the 2011 American Society of Clinical Oncology (ASCO) Annual Meeting regarding the most important developments in the treatment of refractory pancreatic cancer, as they were reported in Abstracts #e14542 and #e14588.
引用
收藏
页码：351 / 354
页数：4
相关论文
共 50 条
  • [41] A phase I study of IRISOX (irinotecan/S-1/oxaliplatin) in the second-line treatment for gemcitabine-refractory pancreatic cancer
    Miyata, E.
    Okuwaki, K.
    Imaizumi, H.
    Kida, M.
    Iwai, T.
    Yamauchi, H.
    Kaneko, T.
    Hasegawa, R.
    Adachi, K.
    Tadehara, M.
    Koizumi, W.
    ANNALS OF ONCOLOGY, 2018, 29
  • [42] Salvage chemotherapy of fixed dose rate gemcitabine and S-1 combination therapy (FGS) for gemcitabine-refractory advanced pancreatic cancer
    Kasuga, A.
    Okano, N.
    Naruge, D.
    Kitamura, H.
    Takasu, A.
    Nagashima, F.
    Furuse, J.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S633 - S634
  • [43] Preclinical combination chemotherapy of nedaplatin with gemcitabine against gemcitabine-refractory human lung cancer
    Takeda, Y
    Wada, T
    Nishitani, Y
    Matsumoto, M
    Hojo, K
    Maekawa, R
    Yoshioka, T
    CANCER LETTERS, 2002, 182 (01) : 61 - 68
  • [44] Randomised phase II trial of irinotecan plus S-1 in patients with gemcitabine-refractory pancreatic cancer
    T Ioka
    Y Komatsu
    N Mizuno
    A Tsuji
    S Ohkawa
    M Tanaka
    H Iguchi
    A Ishiguro
    M Kitano
    T Satoh
    T Yamaguchi
    K Takeda
    M Kida
    K Eguchi
    T Ito
    M Munakata
    T Itoi
    J Furuse
    C Hamada
    Y Sakata
    British Journal of Cancer, 2017, 116 : 464 - 471
  • [45] Randomised phase II trial of irinotecan plus S-1 in patients with gemcitabine-refractory pancreatic cancer
    Ioka, T.
    Komatsu, Y.
    Mizuno, N.
    Tsuji, A.
    Ohkawa, S.
    Tanaka, M.
    Iguchi, H.
    Ishiguro, A.
    Kitano, M.
    Satoh, T.
    Yamaguchi, T.
    Takeda, K.
    Kida, M.
    Eguchi, K.
    Ito, T.
    Munakata, M.
    Itoi, T.
    Furuse, J.
    Hamada, C.
    Sakata, Y.
    BRITISH JOURNAL OF CANCER, 2017, 116 (04) : 464 - 471
  • [46] A phase II study of docetaxel (D) followed by flavopiridol (F) in advanced, gemcitabine-refractory pancreatic cancer (PC)
    Carvajal, R. D.
    Shah, M. A.
    Tse, A.
    Lefkowitz, R.
    Kelsen, D. P.
    Schwartz, G. K.
    O'Reilly, E. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [47] A case of gemcitabine-refractory pancreatic cancer responsive to second-line chemotherapy using S-1
    Morizane, Chigusa
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2007, 37 (12) : 973 - 973
  • [48] The nab-paclitaxel/gemcitabine regimen for patients with refractory advanced pancreatic adenocarcinoma
    Palacio, Sofia
    Hosein, Peter J.
    Reis, Isildinha
    Akunyili, Ikechukwu I.
    Ernani, Vinicius
    Pollack, Terri
    Macintyre, Jessica
    Restrepo, Maria H.
    Merchan, Jaime R.
    Lima, Caio M. Rocha
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2018, 9 (01) : 135 - 139
  • [49] Updates on First-Line Treatment of Metastatic Pancreatic Adenocarcinoma
    Strimpakos, Alexios S.
    Syrigos, Kostas N.
    Saif, Muhammad Wasif
    JOURNAL OF THE PANCREAS, 2011, 12 (04): : 339 - 342
  • [50] A multinational phase II study of PEP02 (liposome irinotecan) for patients with gemcitabine-refractory metastatic pancreatic cancer
    Ko, A. H.
    Tempero, M. A.
    Shan, Y.
    Su, W.
    Lin, Y.
    Dito, E.
    Ong, A.
    Wang, Y.
    Yeh, G.
    Chen, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345